EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Highly Sensitive and Specific Monoclonal Antibodies Against Glypican-1 Using the Cell-Based Immunization and Screening Technology

Haruto Yamamoto, Hiroyuki Suzuki, Tomohiro Tanaka, Mika K. Kaneko, Yukinari Kato

International Journal of Translational Medicine · 25.04.2026 · 6 (2) · 18

DOI: 10.3390/ijtm6020018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Translational Medicine, online erschienen am 25.04.2026. Verfasst von Haruto Yamamoto und 4 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Glypican-1 (GPC1) is a heparan sulfate proteoglycan that plays a critical role in regulating various signaling pathways and tumor development. Overexpression of GPC1 promotes tumor cell proliferation and invasiveness, and is associated with poor clinical outcomes. Therefore, anti-GPC1 monoclonal antibodies (mAbs) have been developed in various modalities for tumor therapy.

Methods

We developed novel anti-GPC1 mAbs using a flow cytometry-based high-throughput screening approach, the Cell-Based Immunization and Screening (CBIS) method.

Results

A clone G1Mab-28 (IgG1, κ) reacted with GPC1-overexpressed Chinese hamster ovary-K1 (CHO/GPC1), but not parental CHO-K1, in flow cytometry. Furthermore, G1Mab-28 recognizes the endogenous GPC1-expressing human esophageal squamous cell carcinoma KYSE770 cell line. Furthermore, G1Mab-28 specifically recognized only CHO/GPC1, but not the other GPC family-overexpressed CHO-K1. The dissociation constant values of G1Mab-28 for CHO/GPC1 and KYSE770 were determined to be 3.3 × 10−8 M and 4.6 × 10−9 M, respectively. Moreover, G1Mab-28 is suitable for Western blotting and immunohistochemistry.

Conclusions

G1Mab-28, established by the CBIS method, is versatile for basic research and is expected to contribute to antibody-based tumor therapy.

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Yamamoto, H., Suzuki, H., Tanaka, T., Kaneko, M. K., & Kato, Y. (2026). Development of Highly Sensitive and Specific Monoclonal Antibodies Against Glypican-1 Using the Cell-Based Immunization and Screening Technology. International Journal of Translational Medicine, 6(2), 18. https://doi.org/10.3390/ijtm6020018

Vancouver

Yamamoto H, Suzuki H, Tanaka T, Kaneko MK, Kato Y. Development of Highly Sensitive and Specific Monoclonal Antibodies Against Glypican-1 Using the Cell-Based Immunization and Screening Technology. International Journal of Translational Medicine. 2026;6(2):18. doi:10.3390/ijtm6020018

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Haruto and Suzuki, Hiroyuki and Tanaka, Tomohiro and Kaneko, Mika K. and Kato, Yukinari},
  title = {Development of Highly Sensitive and Specific Monoclonal Antibodies Against Glypican-1 Using the Cell-Based Immunization and Screening Technology},
  journal = {International Journal of Translational Medicine},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {18},
  doi = {10.3390/ijtm6020018}
}
Kostenlos starten →